HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
1 clinical trials · Condition
◉ Watch HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
| Record | Firm | Date |
|---|---|---|
| The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (NCT07203729) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-03-01 |
Track HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis automatically
Every clearance here is in the API, with alerts when new ones post.